Stelara's primary patent in Europe is set to expire in September 2024, with a specific German patent expiry also expected in the same month [1]. This expiration date is significant for the European market, including Germany.
When does Stelara's exclusivity end?
Stelara's market exclusivity in Europe is tied to its patent protections. The key European patent for Stelara is anticipated to expire in September 2024 [1]. This date marks a critical point for the drug's market.
What happens when Stelara's patent expires?
Once Stelara's patent protection ends, it opens the door for the potential introduction of biosimilar versions of the drug in the European market [2]. Biosimilars are highly similar to the reference biologic drug and are approved by regulatory authorities as safe and effective alternatives [2]. This could lead to increased competition and potentially lower prices for patients and healthcare systems.
Can biosimilars enter before patent expiry?
Generally, biosimilar entry is not permitted before the expiry of relevant patents and other market exclusivity periods [2]. Regulatory bodies assess biosimilar applications based on the scientific evidence of similarity, safety, and efficacy to the reference product.
What is the difference between Stelara and its biosimilars?
Biosimilar versions of Stelara are designed to be highly similar to the original drug in terms of quality, safety, and efficacy [2]. While they are not identical, any minor differences in inactive components are shown not to affect the safety or efficacy of the biosimilar [2]. The development process for biosimilars focuses on demonstrating this high degree of similarity through rigorous scientific comparisons.
Who makes biosimilars for Stelara?
Several companies are developing or have launched biosimilar versions of Stelara. For instance, Amgen has introduced its biosimilar, Amjevita (adalimumab), in the U.S. market, and Samsung Bioepis has developed its biosimilar, Byooviz (ranibizumab), which is also approved in Europe [3][4]. Other companies are also in various stages of development and regulatory approval for their Stelara biosimilars.
When does Stelara's patent expire in the US?
While the question specifically asks about Europe, it is worth noting that Stelara's patent landscape in the U.S. is more complex. Multiple patents cover Stelara, and litigation has been ongoing regarding their validity and potential infringement by biosimilar developers. This has led to varied anticipated expiry dates depending on specific patents and legal outcomes, with some biosimilars facing market entry challenges beyond the initial patent expiry dates [5].
Sources:
1. DrugPatentWatch.com, Stelara European Patent Expiry [1]
2. U.S. Food and Drug Administration, Biosimilar Medicines [2]
3. Amgen, Amjevita [3]
4. Samsung Bioepis, Byooviz [4]
5. DrugPatentWatch.com, Stelara US Patent Expiry [5]